Clary B M, Brady M S, Lewis J J, Coit D G
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Ann Surg. 2001 Feb;233(2):250-8. doi: 10.1097/00000658-200102000-00015.
To analyze the authors' experience with sentinel lymph node biopsy (SLNB) and the subsequent incidence and pattern of recurrence in patients with positive and negative nodes.
Lymphatic mapping with SLNB has become widely accepted in the management of patients with melanoma who are at risk for occult regional lymph node metastases. Because this procedure is relatively new, the pattern of recurrence after SLNB is not yet clear.
All patients with primary cutaneous melanoma who underwent SLNB from 1991 through 1998 were identified from a prospective single-institution melanoma database.
Three hundred fifty-seven consecutive patients with localized primary cutaneous melanoma who underwent SLNB were identified. The sentinel node was identified in 332 patients (93%) and was positive in 56 (17%). Fourteen percent of patients had developed a recurrence at a median follow-up of 24 months. The median time to recurrence was 13 months. The 3-year relapse-free survival rates for patients with positive and negative nodes were 56% and 75%, respectively. SLN status was the most important predictor of disease recurrence. The site of first recurrence in patients with negative and positive nodes was more commonly locoregional than distant. Reexamination of the SLN in 11 patients with negative nodes with initial nodal and in-transit recurrence showed evidence of metastases in 7 (64%).
Patients with positive sentinel nodes have a significantly increased risk for recurrence. The early pattern of first recurrence for patients with negative and positive results is characterized by a preponderance of locoregional sites, similar to that reported in previous series of elective lymph node dissection. These data underscore the need for careful pathologic analysis of the SLN as well as a careful, directed locoregional physical examination in the follow-up of these patients.
分析作者在前哨淋巴结活检(SLNB)方面的经验以及前哨淋巴结阳性和阴性患者后续的复发率及复发模式。
前哨淋巴结活检的淋巴绘图在有隐匿性区域淋巴结转移风险的黑色素瘤患者管理中已被广泛接受。由于该手术相对较新,前哨淋巴结活检后的复发模式尚不清楚。
从一个前瞻性单机构黑色素瘤数据库中识别出1991年至1998年期间接受前哨淋巴结活检的所有原发性皮肤黑色素瘤患者。
确定了357例连续接受前哨淋巴结活检的局限性原发性皮肤黑色素瘤患者。332例(93%)患者找到了前哨淋巴结,其中56例(17%)为阳性。在中位随访24个月时,14%的患者出现了复发。复发的中位时间为13个月。前哨淋巴结阳性和阴性患者的3年无复发生存率分别为56%和75%。前哨淋巴结状态是疾病复发的最重要预测因素。前哨淋巴结阴性和阳性患者首次复发的部位更多为局部而非远处。对11例前哨淋巴结阴性但最初出现区域淋巴结及途中复发的患者重新检查前哨淋巴结,发现7例(64%)有转移证据。
前哨淋巴结阳性的患者复发风险显著增加。前哨淋巴结阴性和阳性患者首次复发的早期模式特点是局部部位占优势,这与先前一系列选择性淋巴结清扫报道的情况相似。这些数据强调了对前哨淋巴结进行仔细病理分析以及对这些患者进行仔细、针对性局部体格检查以进行随访的必要性。